Related Articles
Metastatic renal cell carcinoma regains sensitivity to tyrosine kinase inhibitor after nivolumab treatment: A case report
<em>CD47</em> polymorphism for predicting nivolumab benefit in patients with advanced non‑small‑cell lung cancer
Early blood rise in auto‑antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic‑non‑small cell lung cancer patients treated with PD‑1 immune‑check point blockade by nivolumab
Efficacy and safety of Nivolumab in non‑small cell lung cancer patients in Tel‑Aviv tertiary medical center: Facing the reality
Response to nivolumab in metastatic collecting duct carcinoma expressing PD‑L1: A case report